Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level686 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01295489 | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | — | 39 | Gynecologic Oncology GroupNETWORK | 1 | May 22, 2018 | clinicaltrials |
| NCT02135523 | The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial | completed | N/A | 26 | Yonsei UniversityOTHER | 1 | May 17, 2018 |
| clinicaltrials |
| NCT02270372 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | completed | Phase 1 | 22 | Cascadian Therapeutics Inc.INDUSTRY | 1 | May 17, 2018 | clinicaltrials |
| NCT01570218 | Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy | completed | N/A | 164 | Universidade Federal de GoiasOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT02275039 | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT02107066 | Women's Activity and Lifestyle Study in Connecticut(WALC) | completed | Phase 3 | 144 | Yale UniversityOTHER | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00428610 | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 19, 2018 | clinicaltrials |
| NCT01080521 | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy | completed | — | 247 | Gynecologic Oncology GroupNETWORK | 1 | Apr 12, 2018 | clinicaltrials |
| NCT00746018 | Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy | completed | N/A | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01644825 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer(MITO-11) | completed | Phase 2 | 72 | National Cancer Institute, NaplesOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01869400 | An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer(NIS-OvaYond) | completed | — | 83 | PharmaMar, SpainINDUSTRY | 1 | Apr 6, 2018 | clinicaltrials |
| NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 59 | AccentureINDUSTRY | 3 | Apr 2, 2018 | clinicaltrials |
| NCT00880360 | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer(ONTAK) | completed | Phase 2 | 19 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 27, 2018 | clinicaltrials |
| NCT02877862 | Mobile Phone Technology to Increase Genetic Counseling(mAGIC) | completed | N/A | 104 | University of MinnesotaOTHER | 1 | Mar 27, 2018 | clinicaltrials |
| NCT00587093 | A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer | completed | N/A | 669 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01219777 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | completed | Phase 1 | 9 | Ritu SalaniOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00825201 | Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | completed | Phase 1 | 27 | City of Hope Medical CenterOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00267072 | Ovarian Screening Study | completed | — | 5,000 | University of LouisvilleOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00474669 | A Phase I Study of Intraperitoneal Hyperthermic Docetaxel(IP) | completed | Phase 1 | 30 | University of LouisvilleOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00986206 | Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer | completed | — | 525 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00293293 | Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | completed | N/A | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00381888 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | completed | Phase 2 | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00610740 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | completed | Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00617188 | Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 2 | 26 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01105650 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | completed | Phase 2 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01145430 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02531997 | A Mind-body Intervention to Improve Body and/or Self Image | completed | N/A | 97 | University of MichiganOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01617629 | Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study(CAN-003X) | completed | Phase 2 | 9 | Prima BioMed LtdINDUSTRY | 2 | Dec 8, 2017 | clinicaltrials |
| NCT02118285 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 1 | 2 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01601548 | Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy | completed | N/A | 45 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00005023 | Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer | completed | Phase 1 | — | University of WashingtonOTHER | 1 | Nov 30, 2017 | clinicaltrials |
| NCT00287885 | Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | completed | Phase 1 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00470366 | Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01582906 | A Survivorship Care Plan for Gynaecological Cancer Patients | completed | — | 150 | Royal Marsden NHS Foundation TrustOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT01264432 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 2 | Nov 21, 2017 | clinicaltrials |
| NCT01853306 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | completed | Phase 1 | 71 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02009631 | A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors | completed | Phase 1 | 45 | AbbVieINDUSTRY | 3 | Nov 20, 2017 | clinicaltrials |
| NCT02483104 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | completed | Phase 1 | 9 | AbbVieINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00937560 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 9 | Nov 6, 2017 | clinicaltrials |
| NCT01826227 | Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer | completed | N/A | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02372864 | Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy(PURSUE) | completed | N/A | 66 | University Medical Center GroningenOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT03155451 | Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.(ctDNA_EOC) | completed | — | 43 | RenJi HospitalOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT02374827 | Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)(SCORE) | completed | N/A | 80 | University of Alabama at BirminghamOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT02082470 | Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer | completed | N/A | 14 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2017 | clinicaltrials |
Data updated 24 days agoSource updated May 22, 2018source: clinicaltrials